Oral uracil and tegafur as postoperative adjuvant metronomic chemotherapy in patients with advanced oral squamous cell carcinoma

Lin, Jia-Chuan; Cheng, Chieh-Yuan; Liu, Chung Ji

doi:10.1016/j.jds.2015.03.004

Cited by 6 publications

(12 citation statements)

References 25 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results revealed that patients treated with metronomic UFUR had a significant reduction in the detectable viable CEP cells, which might implicate an antiangiogenesis mechanism behind the survival benefits. The toxicities were mild and manageable, with skin rash (5%) being the most common side-effect, followed by hematological side-effects (2.5%) and nausea/vomiting (2.5%) [103]. Hsieh et al [104] conducted a retrospective study of 356 stage III and IV OCSCC patients.…”

Section: Clinical Evidencementioning

confidence: 99%

“…Although the enteral route for metronomic agents brings convenience and at-home treatment, it should be noted that some OCSCC patients have difficulty in swallowing. This issue matters and affects patient compliance if metronomic chemotherapy is used as adjuvant/maintenance therapy in OCSCC, which might last for 1-2 years [103,104].…”

Section: Advantages and Limitations Of Metronomic Therapy In Ocsccmentioning

confidence: 99%

See 1 more Smart Citation

Metronomic Therapy in Oral Squamous Cell Carcinoma

Chen

2021

JCM

View full text Add to dashboard Cite

Metronomic therapy is characterized by drug administration in a low-dose, repeated, and regular manner without prolonged drug-free interval. The two main anticancer mechanisms of metronomic therapy are antiangiogenesis and immunomodulation, which have been demonstrated in several delicate in vitro and in vivo experiments. In contrast to the traditional maximum tolerated dose (MTD) dosing of chemotherapy, metronomic therapy possesses comparative efficacy but greatlydecreases the incidence and severity of treatment side-effects. Clinical trials of metronomic anticancer treatment have revealed promising results in a variety cancer types and specific patient populations such as the elderly and pediatric malignancies. Oral cavity squamous cell carcinoma (OCSCC) is an important health issue in many areas around the world. Long-term survival is about 50% in locally advanced disease despite having high-intensity treatment combined surgery, radiotherapy, and chemotherapy. In this article, we review and summarize the essence of metronomic therapy and focus on its applications in OCSCC treatment.

show abstract

Section: Clinical Evidencementioning

confidence: 99%

Section: Advantages and Limitations Of Metronomic Therapy In Ocsccmentioning

confidence: 99%

Metronomic Therapy in Oral Squamous Cell Carcinoma

Chen

2021

JCM

View full text Add to dashboard Cite

show abstract

“…One study set two groups including 75 mg/m² docetaxel every 21 days and 75 mg/m² docetaxel pulse 40mg AT-101 twice daily for 3 days, which was different in using of AT-101 compared with metronomic group [18]. And one study did not give other therapies after surgery which de ned as blank control [20].…”

Section: Treatment Regimensmentioning

confidence: 99%

“…Then 67 records including 9 comments or abstracts related to the aim of study were excluded. Finally, 13 records meeting criteria, including 3 randomized control trails [17][18][19], 1 cohort study [20], 4 prospective studied (3 single arm trials [21][22][23], 1 match pair analysis [24]) and 5 retrospective studies [25][26][27][28][29] were included.…”

Section: Study Selectionmentioning

confidence: 99%

“…In terms of tumor location, oral cavity occupied the most proportion, and next were pharynx and larynx. Most studies reported Eastern Cooperative Oncology Group performance status score of participants, except one study that used the Karnofsky Performance Status [19] and three studies did not report which standard they used [20,27,28]. Four studies reported their dropout or loss data [17,19,21,23], while remaining did not give the information.…”

Section: Study Characteristicmentioning

confidence: 99%

See 1 more Smart Citation

The Effectiveness and Safety of Metronomic Chemotherapy in Patients with Head and Neck Carcinoma: A Systematic Review and Meta-analysis

Wang

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Head and neck carcinoma, usually begins in the squamous cells, not only seriously endangers the quality of life, but brings a heavy financial burden for families and countries. Metronomic chemotherapy, a frequent administration of chemotherapeutic agents at a non-toxic dose, gives an alternative low-cost and tolerated approach for patients. We conducted a systematic review to find the effectiveness and safety of metronomic chemotherapy for head and neck cancer.Methods: We searched seven databases and Clinical.gov from the inception to July 14, 2021. The patients diagnosed head and neck cancer and older than 18 were included. Metronomic chemotherapy was defined as intervention. Randomized and non-randomized trials were all included. Quality assessment of included randomized control trials was performed using the Cochrane Risk-of-Bias criteria, cohort studies using The Newcastle-Ottawa Scale (NOS), single arm trials using the checklist recommended by The Agency for Healthcare Research and Quality (AHRQ). Studies were synthetized using a narrative approach. The indicators used for meta-analysis was hazard ratio (HR).Results: 310 Literatures were potentially eligible from 7 databases, finally 13 records were included. Five studies were of high quality, while eight were of moderate quality. The overall effect of HR for death of five trials reported had no statistically significant (HR=0.89, 95%CI 0.71-1.10). Subgroup analysis by different design showed a statistically significant HR (0.73, 95%CI 0.60-0.90) in randomized control trials while no significant difference in subgroup of prospective study design (HR=1.23, 95%CI 0.72-2.10). As for HR for PFS, there was no significant difference in overall effect of four studies. HR for PFS was 0.84 (95%CI 0.55-1.31). Subgroup analysis of study design showed that randomized control trials produced a significant HR (0.54, 95%CI 0.45-0.64), while prospective studies did not (1.25, 95%CI 0.73, 2.14).Conclusions: Metronomic chemotherapy has been an optimistic option for treatment for advanced head and neck cancer, especially in low income and medical resource-restricted regions.

show abstract